These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Activation of cannabinoid type 1 receptors decreases the synchronization of local field potential oscillations in the hippocampus and entorhinal cortex and prolongs the interresponse time during a differential-reinforcement-of-low-rate task. Liao WT; Chang CL; Hsiao YT Eur J Neurosci; 2020 Nov; 52(10):4249-4266. PubMed ID: 32510690 [TBL] [Abstract][Full Text] [Related]
49. Targeting mediodorsal thalamic CB1 receptors to inhibit dextromethorphan-induced anxiety/exploratory-related behaviors in rats: The post-weaning effect of exercise and enriched environment on adulthood anxiety. Banaei-Boroujeni G; Rezayof A; Alijanpour S; Nazari-Serenjeh F J Psychiatr Res; 2023 Jan; 157():212-222. PubMed ID: 36495603 [TBL] [Abstract][Full Text] [Related]
50. The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids. Crocker PJ; Mahadevan A; Wiley JL; Martin BR; Razdan RK Bioorg Med Chem Lett; 2007 Mar; 17(6):1504-7. PubMed ID: 17257842 [TBL] [Abstract][Full Text] [Related]
51. Cb1 receptor-mediated signaling emerges as a novel lead to evidence-based treatment development for stress-related psychopathology. Bailey CR; Neumeister A Neurosci Lett; 2011 Sep; 502(1):1-4. PubMed ID: 21787837 [No Abstract] [Full Text] [Related]
52. Impact of At Least 2 Years of Synthetic Cannabinoid Use on Cognitive and Psychomotor Functions Among Treatment-Seeking Male Outpatients. Umut G; Evren C; Atagun MI; Hisim O; Yilmaz Cengel H; Bozkurt M; Keskinkilic C Cannabis Cannabinoid Res; 2020 Jun; 5(2):164-171. PubMed ID: 32656348 [No Abstract] [Full Text] [Related]
53. Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization. Yohn SE; Arif Y; Haley A; Tripodi G; Baqi Y; Müller CE; Miguel NS; Correa M; Salamone JD Psychopharmacology (Berl); 2016 Oct; 233(19-20):3575-86. PubMed ID: 27497935 [TBL] [Abstract][Full Text] [Related]
54. A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Δ(9)-THC in rats. Järbe TU; LeMay BJ; Thakur GA; Makriyannis A Pharmacol Biochem Behav; 2016 Sep; 148():46-52. PubMed ID: 27264437 [TBL] [Abstract][Full Text] [Related]
55. CB1 antagonism produces behaviors more consistent with satiety than reduced reward value in food-maintained responding in rats. Thompson EE; Jagielo-Miller JE; Vemuri VK; Makriyannis A; McLaughlin PJ J Psychopharmacol; 2016 May; 30(5):482-91. PubMed ID: 27005309 [TBL] [Abstract][Full Text] [Related]
56. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897 [TBL] [Abstract][Full Text] [Related]
57. Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. Nunes EJ; Randall PA; Estrada A; Epling B; Hart EE; Lee CA; Baqi Y; Müller CE; Correa M; Salamone JD Psychopharmacology (Berl); 2014 Feb; 231(4):727-36. PubMed ID: 24136220 [TBL] [Abstract][Full Text] [Related]
58. Effects of a novel CB1 agonist on visual attention in male rats: role of strategy and expectancy in task accuracy. Miller RL; Thakur GA; Stewart WN; Bow JP; Bajaj S; Makriyannis A; McLaughlin PJ Exp Clin Psychopharmacol; 2013 Oct; 21(5):416-25. PubMed ID: 24099361 [TBL] [Abstract][Full Text] [Related]
59. Synthesis and characterization of 2-substituted bornane pharmacophores for novel cannabinergic ligands. Duclos RI; Lu D; Guo J; Makriyannis A Tetrahedron Lett; 2008 Sep; 49(39):5587-5589. PubMed ID: 23935221 [TBL] [Abstract][Full Text] [Related]